Project Details
Description
A Phase 1/2 Study of Tegavivint (IND#156033, NSC#826393) in Children, Adolescents, and Young Adults with Recurrent or Refractory Solid Tumors, Including Lymphomas and Desmoid Tumors
| Status | Active |
|---|---|
| Effective start/end date | 10/15/21 → 10/14/24 |
Funding
- PUBLIC HEALTH INSTITUTE
- ITERION THERAPEUTICS, INC.
Fingerprint
Explore the research topics touched on by this project. These labels are generated based on the underlying awards/grants. Together they form a unique fingerprint.